Network pharmacology-based identification of key pharmacological pathways of yin–huang–qing–fei capsule acting on chronic bronchitis

International Journal of COPD

Volumn 12, Issue , 2016, Pages 85-94

  Yu, Guohua ^a,b   Zhang, Yanqiong ^b   Ren, Weiqiong ^c   Dong, Ling ^a   Li, Junfang ^b,d   Geng, Ya ^b,e   Zhang, Yi ^b   Li, Defeng ^b   Xu, Haiyu ^b   Yang, Hongjun ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c THE FIRST HOSPITAL OF HUNAN UNIVERSITY OF CHINESE MEDICINE   (China)

^d TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Asthma pathway; Chronic bronchitis; Network pharmacology; Traditional Chinese medicine; Yin huang qing fei capsule

Indexed keywords

EOSINOPHIL PEROXIDASE; EOTAXIN; FC EPSILON RI RECEPTOR; FC RECEPTOR; HERBACEOUS AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; UNCLASSIFIED DRUG; YIN HUANG QING FEI; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; AUTACOID; MICROCAPSULE; PROTEIN BINDING; YIN-HUANG-QING-FEI;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; DRUG DATABASE; DRUG TARGETING; HERB; IMMUNE RESPONSE; MOLECULAR DOCKING; NETWORK LEARNING; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; BRONCHITIS, CHRONIC; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; LUNG; METABOLISM; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROCEDURES; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY;

ADMINISTRATION, ORAL; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHITIS, CHRONIC; CAPSULES; DRUGS, CHINESE HERBAL; HUMANS; INFLAMMATION MEDIATORS; LUNG; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SYSTEMS BIOLOGY;

EID: 85007553378     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S121079     Document Type: Article

References (69)

1. Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis. 2007;2(3):191–204.
2. Ko HJ, Oh SK, Jin JH, Son KH, Kim HP. Inhibition of experimental systemic inflammation (septic inflammation) and chronic bronchitis by new phytoformula BL containing Broussonetia papyrifera and Lonicera japonica. Biomol Ther (Seoul). 2013;21(1):66–71.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):442–442.
4. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med. 2013;369(14):1336–1343.
5. Liu S, Shergis J, Chen X, et al. Chinese herbal medicine (Weijing decoction) combined with pharmacotherapy for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Evid Based Complement Alternat Med. 2014;2014(8):1–12.
6. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(suppl 2):S28–S38.
7. Liu W, Jiang H, Zhang R, et al. Efficacy and safety of Qing-Feng-Gan-Ke granules in patients with postinfectious cough: study protocol of a novel-design phase III placebo-controlled, double-blind randomized trial. BMC Complement Altern Med. 2015;15(1):1–11.
8. Tao W, Xu X, Wang X, et al. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal radix curcumae formula for application to cardiovascular disease. J Ethnopharmacol. 2013;145(1):1–10.
9. Li XM. Traditional Chinese herbal remedies for asthma and food allergy. J Allergy Clin Immunol. 2007;120(1):25–31.
10. Ye HF, Xie HB. Effect and clinical observation of Yinghuang Qingfei capsules on the hemorrheology of patients with acute exacerbation of chronic obstructive pulmonary disease. China Pharm. 2015;2015(11):1536–1538.
11. Wang D, Cai T, Wu ZJ, et al. LC-ESI-MS/MS analysis of chemical constituents in Yinhuang Qingfei capsule. China Meas Test. 2016;42(03):36–40.
12. Li XL, Lu FG, Yi DF, et al. Experimental research on the function of anti-influenza virus in vitro of Yinhuang Qingfei capsules containing serum. Chin Arch Tradit Chin Med. 2015;2015(05):1107–1109.
13. Peng Z, Lu FG, Qu JY, et al. Experimental research of Yinhuang Qingfei capsules containing serum on the respiratory syncytial virus in vitro. J Hunan Univ Chin Med. 2016;36(02):40–43.
14. Liang X, Li H, Li S. A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-Wei-Di-Huang pill as a case study. Mol Biosyst. 2014;10(5):1014–1022.
15. Wang S, Tong Y, Ng TB, et al. Network pharmacological identification of active compounds and potential actions of Erxian decoction in alleviating menopause-related symptoms. Chin Med. 2015;10(1):1–12.
16. Zhang GB, Li QY, Chen QL, et al. Network pharmacology: a new approach for Chinese herbal medicine research. Evid Based Complement Alternat Med. 2013;2013(8):1–9.
17. Li S, Zhang B, Jiang D, Wei Y, Zhang N. Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. BMC Bioinformatics. 2010;11(suppl 11):S1–S12.
18. Zhao F, Guochun L, Yang Y, Shi L, Xu L, Yin L. A network pharmacology approach to determine active ingredients and rationality of herb combinations of modified-Simiaowan for treatment of gout. J Ethnopharmacol. 2015;168:1–16.
19. Zhang YQ, Wang SS, Zhu WL, et al. Deciphering the pharmacological mechanism of the Chinese formula Huanglian-Jie-Du decoction in the treatment of ischemic stroke using a systems biology-based strategy. Acta Pharmacol Sin. 2015;36(6):724–733.
20. Sheng S, Wang J, Wang L, et al. Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong capsule with experimental support using disseminated intravascular coagulation rats. J Ethnopharmacol. 2014;154(3):735–744.
21. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian inheritance in man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 2005;33(suppl 1):S514–S517.
22. Xu H, Tao Y, Lu P, et al. A computational drug-target network for Yuanhu Zhitong prescription. Evid Based Complement Alternat Med. 2013;2013(1):70–75.
23. Chen JY, Mamidipalli S, Huan T. HAPPI: an online database of comprehensive human annotated and predicted protein interactions. BMC Genomics. 2009;10(suppl 1):S1–S11.
24. D’Eustachio P. Reactome knowledgebase of human biological pathways and processes. Bioinform Comp Proteomics. 2009;37(37):49–61.
25. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics. 2005;21(9):2076–2082.
26. Kerrien S, Aranda B, Breuza L, et al. The IntAct molecular interaction database in 2012. Nucleic Acids Res. 2012;40(21):841–846.
27. Prasad TK, Kandasamy K, Pandey A. Human protein reference database and human proteinpedia as discovery tools for systems biology. Methods Mol Biol. 2009;577(577):67–79.
28. Ceol A, Aryamontri AC, Licata L, et al. MINT, the molecular interaction database: 2009 update. Nucleic Acids Res. 2009;38:532–539.
29. Lehne B, Schlitt T. Protein-protein interaction databases: keeping up with growing interactomes. Hum Genomics. 2009;3(3):291–297.
30. Beuming T, Skrabanek L, Niv MY, et al. PDZBase: a protein–protein interaction database for PDZ-domains. Bioinformatics. 2005;21(6):827–828.
31. Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, Wang YY. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 2007;1(1):51–60.
32. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):3–3.
33. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
34. Steinke JW, Borish L. Cytokines and chemokines. J Allergy Clin Immunol. 2006;117(2):441–445.
35. Kumar V, Abbas AK, Aster JC, et al. Robbins and Cotran Pathologic Basis of Disease. 4th ed. Pennsylvania: Elsevier Saunders; 2005.
36. PlattsMills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164(8 pt 2):1–5.
37. Bjermer L, Diamant Z. Current and emerging nonsteroidal anti-inflammatory therapies targeting specific mechanisms in asthma and allergy. Treat Respir Med. 2004;3(3):235–246.
38. Nakae S, Ho LH, Yu M, et al. Mast cell–derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J Allergy Clin Immunol. 2007;120(1):48–55.
39. Zeiger RS, Schatz M, Li Q, et al. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract. 2014;2(6):741–750.
40. Shokry DM, Eltarahony SA. Oxidant-antioxidant balance in childhood asthma. Egypt J Pediatr Allergy Immunol. 2013;11(1):35–40.
41. Lee IT, Yang CM. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochem Pharmacol. 2012;84(5):581–590.
42. Reszka KJ, Sallans L, Macha S, et al. Airway peroxidases catalyze nitration of the {beta}2-agonist salbutamol and decrease its pharmacological activity. J Pharmacol Exp Ther. 2011;336(2):440–449.
43. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47–95.
44. Evans P, Halliwell B. Micronutrients: oxidant/antioxidant status. Br J Nutr. 2001;85(suppl 2):S67–S74.
45. Chaudière J, Ferrari-Iliou R. Intracellular antioxidants: from chemical to biochemical mechanisms. Food Chem Toxicol. 1999;37(9–10):949–962.
46. Brozovich FV, Nicholson CJ, Degen CV, Gao YZ, Aggarwal M, Morgan KG. Mechanisms of vascular smooth muscle contraction and the basis for pharmacologic treatment of smooth muscle disorders. Pharmacol Rev. 2016;68(2):476–532.
47. Nadeem A, Siddiqui N, Alharbi NO, Alharbi MM. Airway and systemic oxidant-antioxidant dysregulation in asthma: a possible scenario of oxidants spill over from lung into blood. Pulm Pharmacol Ther. 2014;29(1):31–40.
48. Franova S, Nosal’Ova G. ACE-inhibitors and defence reflexes of the airways. Acta Physiol Hung. 1997;85(4):359–366.
49. Gunawardhana LP, Gibson PG, Simpson JL, Benton MC, Lea RA, Baines KJ. Characteristic DNA methylation profiles in peripheral blood monocytes are associated with inflammatory phenotypes of asthma. Epigenetics. 2014;9(9):1302–1316.
50. Abebe W, Mustafa SJ. A1 adenosine receptor-mediated Ins(1,4,5)P3 generation in allergic rabbit airway smooth muscle. Am J Physiol. 1998;275(5):990–997.
51. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218–230.
52. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002;2(6):446–453.
53. Wu K, Bi Y, Sun K, Wang C. IL-10-producing type 1 regulatory T cells and allergy. Cell Mol Immunol. 2007;4(4):269–275.
54. Grünig G, Corry DB, Leach MW, Seymour BW, Kurup VP, Rennick DM. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J Exp Med. 1997;185(6):1089–1099.
55. Nelson HS, Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J Allergy Clin Immunol. 2003;111(2):215–225.
56. Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21(1):425–456.
57. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282(5397):2261–2263.
58. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as “tunable” effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749–786.
59. Renauld J-C. New insights into the role of cytokines in asthma. J Clin Pathol. 2001;54(8):577–589.
60. Cieslewicz G, Tomkinson A, Adler A, et al. The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J Clin Invest. 1999;104(3):301–308.
61. Dombrowicz D, Capron M. Eosinophils, allergy and parasites. Curr Opin Immunol. 2001;13(6):716–720.
62. Wu W, Samoszuk MK, Comhair SA, et al. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest. 2000;105(10):1455–1463.
63. Van CE, Van DJ, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999;10(1):61–86.
64. Ponath PD, Qin S, Ringler DJ, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996;97(3):604–612.
65. Kodali RB, Kim WJ, Galaria II, et al. CCL11 (eotaxin) induces CCR3-dependent smooth muscle cell migration. Arterioscler Thromb Vasc Biol. 2004;24(7):1211–1216.
66. Rankin SM, Conroy DM, Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today. 2000;6(1):20–27.
67. Heath H, Qin S, Rao P, et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest. 1997;99(2):178–184.
68. Zhang G, Li Q, Chen Q, Su S. Network pharmacology: a new approach for Chinese herbal medicine research. Evid Based Complement Alternat Med. 2013;2013(8):621423–621423.
69. Ai G, Tian C, Deng D, et al. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors. Anticancer Drugs. 2015;26(4):399–409.